NeuroSense Therapeutics Ltd., a clinical-stage biotechnology company, focuses on discovering and developing treatments for patients suffering from neurodegenerative diseases in the United States and internationally. The company's lead product is PrimeC, an extended-release oral formulation of a fixed-dose combination of ciprofloxacin and celecoxib, currently under Phase 2b/3 clinical trials for the treatment of amyotrophic lateral sclerosis, and completed Phase 2 clinical trials for the treatment of Alzheimer's, as well as under preclinical studies for the treatment of Parkinson's disease. Its preclinical pipeline includes StabiliC for the treatment of Parkinson's disease; and CogniC for the treatment of Alzheimer's disease. NeuroSense Therapeutics Ltd. was incorporated in 2017 and is headquartered in Herzliya, Israel.
Frequently asked questions
What sector does NeuroSense Therapeutics Ltd. Warrant (NRSNW) operate in?
NeuroSense Therapeutics Ltd. Warrant belongs to the Healthcare sector and operates in the industry.
What is NeuroSense Therapeutics Ltd. Warrant (NRSNW) current stock price?
As of the latest data, NeuroSense Therapeutics Ltd. Warrant stock price is $0.12, with a previous close of $0.12.
What is NeuroSense Therapeutics Ltd. Warrant (NRSNW) current market capitalization?
NeuroSense Therapeutics Ltd. Warrant market cap is approximately 3.03 million.
What is NeuroSense Therapeutics Ltd. Warrant (NRSNW) Earnings Per Share (EPS)?
The trailing EPS is -$0.94.
Does NeuroSense Therapeutics Ltd. Warrant (NRSNW) pay dividends?
No. NeuroSense Therapeutics Ltd. Warrant does not pay a dividend.
What is NeuroSense Therapeutics Ltd. Warrant (NRSNW) beta (volatility) score?
NeuroSense Therapeutics Ltd. Warrant has a beta of 1.598, suggesting it is more volatile than the market.
